Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

Xiaoning Wu,1–3,* Jialing Zhou,1–3,* Wen Xie,4 Huiguo Ding,5 Xiaojuan Ou,1–3 Guofeng Chen,6 Anlin Ma,7 Xiaoyuan Xu,8 Hui Ma,9 Youqing Xu,10 Xiaoqing Liu,11 Tongtong Meng,1–3 Lin Wang,1–3 Yameng Sun,1–3 Bingqiong Wang,1–3 Yuanyuan...

Full description

Bibliographic Details
Main Authors: Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, Ma A, Xu X, Ma H, Xu Y, Liu X, Meng T, Wang L, Sun Y, Wang B, Kong Y, You H, Jia J
Format: Article
Language:English
Published: Dove Medical Press 2019-04-01
Series:Infection and Drug Resistance
Subjects:
Entecavir
de novo combination
lamivudine
adefovir
compensated HBV-related cirrhosis
real-world
virological breakthrough
Online Access:https://www.dovepress.com/entecavir-monotherapy-versus-de-novo-combination-of-lamivudine-and-ade-peer-reviewed-article-IDR

Internet

https://www.dovepress.com/entecavir-monotherapy-versus-de-novo-combination-of-lamivudine-and-ade-peer-reviewed-article-IDR

Similar Items